Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Antiviral therapy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    413 result(s) found for: Antiviral therapy. Displaying page 1 of 21.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2009-012344-17 Sponsor Protocol Number: CICL670AIT06T Start Date*: 2009-10-13
    Sponsor Name:AZIENDA OSPEDALIERA POLICLINICO DI MODENA
    Full Title: A randomized, open label, single center, phase IIa controlled trial to assess tolerability, safety and effect of treatment with deferasirox plus standard antiviral therapy versus standard antivira...
    Medical condition: Chronic hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008912 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-001032-54 Sponsor Protocol Number: 19PH192 Start Date*: 2019-07-23
    Sponsor Name:CHU de Saint Etienne
    Full Title: Impact of anti-cytomegalovirus (valganciclovir) treatment in the management of relapsing ulcerative colitis (UC) requiring vedolizumab therapy: a randomized clinical trial comparing a strategy with...
    Medical condition: Patient with active ulcerative colitis who failed to anti-TNF with endoscopic active disease with an endoscopic Mayo score> 1 and 2 biopsies of the inflammatory tissue and presence of a CMV infect...
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    20.1 100000004862 10058881 Cytomegalovirus viremia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-001469-16 Sponsor Protocol Number: TPL102357 Start Date*: 2005-10-20
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A double-blind, randomized, placebo-controlled, multi-centre, dose-ranging, parallel group, phase II study to assess efficacy, safety/tolerability, and pharmacokinetics of a thrombopoietin receptor...
    Medical condition: Thrombocytopenia caused by hepatitis-C
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-004953-26 Sponsor Protocol Number: BHS-TC13 Start Date*: 2016-03-11
    Sponsor Name:Ghent University Hospital
    Full Title: CMV specific T cell therapy for the treatment of relapsing or therapy refractory CMV infection after allogeneic stem cell transplantation with a CMV-positive donor.
    Medical condition: CMV specific T cell therapy for the treatment of relapsing or therapy refractory CMV infection after allogeneic stem cell transplantation with a CMV-positive donor.
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-004442-15 Sponsor Protocol Number: HISTORY Start Date*: 2013-09-11
    Sponsor Name:University Leipzig
    Full Title: High-dose intravenous silibinin infusions during 10 days as add-on treatment to triple therapy (telaprevir, peginterferon alpha and ribavirin) in cirrhotic GT 1 hepatitis C virus infected patients ...
    Medical condition: High-dose intravenous silibinin infusions during 10 days as add-on treatment to triple therapy (telaprevir, peginterferon alpha and ribavirin) in cirrhotic GT 1 hepatitis C virus infected patients ...
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004871 10019642 Hepatic cirrhosis NOS LLT
    16.1 100000004848 10072848 Hepatitis C virus genotype 1 positive LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-003648-70 Sponsor Protocol Number: ML 19365 Start Date*: 2007-02-08
    Sponsor Name:Charité Universitätsmedizin Berlin
    Full Title: Randomised, double-blinded phase IIIb study to optimise antiviral therapy response of a standard therapy consisting of peginterferon-alfa-2a and ribavirin plus the additional use of bezafibrat 400 ...
    Medical condition: First time treatment in chronic hepatitis C-infection patients with elevated GGT-level without coinfections as HBV, HDV and HIV
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-000245-39 Sponsor Protocol Number: LEG-SIL-2-01 Start Date*: 2013-09-11
    Sponsor Name:Rottapharm S.p.A
    Full Title: Rescue effect of daily infusions with Legalon® SIL in Hepatitis C Virus-infected patients who are incomplete responders to standard pegylated interferon/ribavirin (dual therapy) or pegylated interf...
    Medical condition: HCV infected patients who are incomplete responders to standard pegylated interferon/ribavirin (dual therapy) or pegylated interferon/ribavirin plus a protease inhibitor (triple therapy)
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004848 10066936 HCV viral load LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-001283-37 Sponsor Protocol Number: GE-ARNICA-2008 Start Date*: 2007-09-24
    Sponsor Name:AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA
    Full Title: Chronic hepatitis C in illicit drug users and the role of antiviral therapy: the ARNICA project (Antiviral tReatment for chroNic hepatItis C in Active substance users)
    Medical condition: Chronic Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019715 Hepatic viral infections HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-003201-81 Sponsor Protocol Number: GFVT01026904 (GACHE) Start Date*: 2006-12-20
    Sponsor Name:Universitätsklinikum Heidelberg
    Full Title: GACHE: German trial of Acyclovir and Corticosteroids in Herpes-simplex-virus-Encephalitis. A multicenter, multinational, randomized, double-blind, placebo-controlled German, Austrian and Dutch trial.
    Medical condition: Herpes simplex virus type-1 (HSV-1) is the most frequent cause of fatal sporadic encephalitis in humans. Herpes simplex encephalitis (HSE) was one of the first viral infections to be successfully t...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-012436-32 Sponsor Protocol Number: IVIST01 Start Date*: Information not available in EudraCT
    Sponsor Name:Medizinische Hochschule Hannover
    Full Title: A multicenter, randomized, open-labeled study to steer immunsuppressive and antiviral therapy by measurement of virus- (CMV, ADV, HSV) specific T cells in addition to determination of trough levels...
    Medical condition: After solid organ transplantation immunosuppressive treatment disrupts the individual balance between virus-replication and cellular immune response. This can lead to an elevated risk of severe vir...
    Disease: Version SOC Term Classification Code Term Level
    19.1 10042613 - Surgical and medical procedures 10052279 Renal and liver transplant PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-001705-26 Sponsor Protocol Number: CYD-GER-0401 Start Date*: 2005-09-21
    Sponsor Name:Spirig Pharma AG
    Full Title: Efficacy and safety of topically applied cyclodextrin gel (Spirig Pharma) in the treatment of recurrent genital herpes simplex virus infections: a randomised, double-blind, placebo-controlled, mult...
    Medical condition: Genito-anal herpes simplex infections
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-002696-40 Sponsor Protocol Number: ACH171-002 Start Date*: 2006-10-12
    Sponsor Name:Achillion Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Multiple Doses of ACH-0137171 in Subjects w...
    Medical condition: Chronic Hepatitis C Infection
    Disease: Version SOC Term Classification Code Term Level
    8.1 10008912 Chronic hepatitis C LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-001789-28 Sponsor Protocol Number: IG1601 Start Date*: 2018-04-25
    Sponsor Name:Instituto Grifols S.A.
    Full Title: Prevention of Mortality with Long-Term Administration of Human Albumin in Subjects with Decompensated Cirrhosis and Ascites
    Medical condition: Subjects with decompensated cirrhosis and ascites
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10064704 Decompensated cirrhosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) FR (Completed) BE (Completed) GB (GB - no longer in EU/EEA) DK (Completed) IT (Completed) HU (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2006-004946-17 Sponsor Protocol Number: TPL103922 Start Date*: 2007-11-02
    Sponsor Name:GlaxoSmithKline S.A. España
    Full Title: Estudio multicéntrico aleatorizado, controlado con placebo, para evaluar la eficacia y la seguridad de eltrombopag en sujetos trombocitopénicos infectados por el virus de la hepatitis C (VHC) que, ...
    Medical condition: Sujetos trombocitopénicos con infección vírica por Hepatitic C. Thrombocytopenic subjects with hepatitis C viral infection.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019744 Hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed) BE (Completed) NL (Completed) IT (Completed) CZ (Completed) GB (Completed) SK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-002781-21 Sponsor Protocol Number: CO11/9730 Start Date*: 2012-02-02
    Sponsor Name:Leeds Teaching Hospitals
    Full Title: A clinical study to evaluate the biological effects of administering rimantadine in patients with hepatitis C virus (HCV) infection alongside standard combination therapy with pegylated interferon ...
    Medical condition: Hepatitis C Virus infection - genotype 1. Genotype 1 is least responsive to current treatment and is the focus of this study. HCV can cause severe liver damage - this study will only recruit those ...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-022568-11 Sponsor Protocol Number: AI452-008 Start Date*: 2011-04-20
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: A Phase 2B, randomized study to evaluate the safety and efficacy of Pegylated Interferon Lambda (BMS-914143) administered with Ribavirin plus a single direct antiviral agent (BMS-790052 or BMS-6500...
    Medical condition: Chronic Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-003865-33 Sponsor Protocol Number: CCR100136 Start Date*: 2005-02-03
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Phase IIb, 96 week, randomized, open-label, multicenter, parallel group, repeat dose study to evaluate the safety, tolerability, pharmacokinetics and antiviral effect of different doses and regim...
    Medical condition: Treatment of HIV-1 infection
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) IT (Prematurely Ended) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-000292-42 Sponsor Protocol Number: TPL108390 Start Date*: 2007-12-06
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: ENABLE 2 (Eltrombopag to INitiate and Maintain Interferon Antiviral Treatment to Benefit Subjects with Hepatitis C related Liver DiseasE) Randomised, placebo-controlled, multi-centre study to asses...
    Medical condition: Thrombocytopenic subjects with hepatitis C viral infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019744 Hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) GR (Completed) BE (Completed) ES (Completed) IT (Completed) CZ (Completed) SK (Completed) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-000660-17 Sponsor Protocol Number: TPL108392 Start Date*: 2009-07-29
    Sponsor Name:GlaxoSmithKline
    Full Title: TPL108392: An open-label, multi-centre rollover study to assess the safety and efficacy of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligibl...
    Medical condition: Thrombocytopenic subjects with hepatitis C viral infection (HCV)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019744 Hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) DE (Completed) ES (Completed) FR (Completed) IT (Completed) GR (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-018197-66 Sponsor Protocol Number: 1241.21 Start Date*: 2010-04-29
    Sponsor Name:Unilfarma, Lda.
    Full Title: Safety, antiviral effect and pharmacokinetics of BI 207127 in combination with BI 201335 and with or without ribavirin for 4, 16, 24, 28 or 40 weeks in patients with chronic HCV genotype 1 infectio...
    Medical condition: chronic hepatitis C infection of genotype 1
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004848 10019751 Hepatitis C virus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) FR (Completed) DE (Completed) AT (Completed) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 07 08:54:24 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA